2,740 results match your criteria: "Siteman Cancer Center[Affiliation]"
Cardiooncology
November 2024
Cardio-Oncology Center of Excellence, Cardiovascular Division, Washington University School of Medicine, St. Louis, MO, USA.
Background: Patients with non-small cell lung cancer (NSCLC) undergoing thoracic radiation are at high cardiovascular risk. Semiquantitative assessment of coronary artery calcification (CAC) on baseline planning non-gated chest computed tomography (CT) scans may help further risk stratify patients.
Objectives: This study aimed to characterize the association between CAC and major adverse cardiovascular events (MACE; myocardial infarction or stroke) and assess the utility of semiquantitative assessment of CAC.
Cancer
January 2025
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Trends Pharmacol Sci
December 2024
Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA; Department of Pathology & Immunology, Washington University School of Medicine, St Louis, MO 63110, USA; Siteman Cancer Center, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address:
Pancreatic adenocarcinoma (PDAC) has been historically unresponsive to immunotherapy, predominantly due to lower antigen loads and a lack of tumor-infiltrating dendritic cells (DCs) and T cells. A recent study by Mahadevan and colleagues demonstrates that increasing DC infiltration through use of an engineered DC1 vaccine can sensitize PDAC to immunotherapy.
View Article and Find Full Text PDFBr J Cancer
November 2024
Department of Radiation Oncology, Washington University in St Louis, Saint Louis, MO, USA.
Sci Rep
November 2024
Mallinckrodt Institute of Radiology, Washington University in St. Louis School of Medicine, Mail Stop Code: 8131, 4559 Scott Ave, St. Louis, MO, 63110, USA.
Clinically, the body mass index remains the most frequently used metric of overall obesity, although it is flawed by its inability to account for different adipose (i.e., visceral, subcutaneous, and inter/intramuscular) compartments, as well as muscle mass.
View Article and Find Full Text PDFFront Oncol
October 2024
Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, United States.
Since their initial approval as single agent therapy for multiply relapsed/refractory Hodgkin lymphoma (HL), the PD-1 inhibitors nivolumab and pembrolizumab have been incorporated into second-line salvage regimens, and they are being investigated in upfront therapy of newly diagnosed patients. As second-line therapy in combination with brentuximab vedotin or multi-agent chemotherapy, nivolumab and pembrolizumab provide high complete remission rates and durable progression-free survival after consolidative autologous stem cell transplant. Incorporation of these agents into frontline chemotherapy regimens is feasible, and early results from a Phase III trial of nivolumab-AVD compare favorably with the existing standard for advanced stage HL, brentuximab vedotin plus AVD.
View Article and Find Full Text PDFGynecol Oncol
December 2024
Gynecologic Oncology Program, AdventHealth Cancer Institute, Orlando, FL, USA.
Background/objectives: Patients with recurrent or metastatic endometrial cancer (EC) have poor prognoses with limited therapeutic options following immunotherapy or immunochemotherapy treatments. Inhibitors of KRAS mutations (KRAS-mut) have shown efficacy in early solid tumor studies, but data in EC are lacking. This study describes the frequency of KRAS-mut relative to other oncogenic alterations in EC to identify genomic characteristics of KRAS-mut tumors that could lead to novel therapeutic options.
View Article and Find Full Text PDFRes Sq
October 2024
Department of Internal Medicine, Division of Oncology, School of Medicine, Washington University in St. Louis, MO, 631101.
Nature
October 2024
Department of Medicine, Washington University in St Louis, St Louis, MO, USA.
To study the spatial interactions among cancer and non-cancer cells, we here examined a cohort of 131 tumour sections from 78 cases across 6 cancer types by Visium spatial transcriptomics (ST). This was combined with 48 matched single-nucleus RNA sequencing samples and 22 matched co-detection by indexing (CODEX) samples. To describe tumour structures and habitats, we defined 'tumour microregions' as spatially distinct cancer cell clusters separated by stromal components.
View Article and Find Full Text PDFNat Methods
December 2024
Department of Computer Science, Princeton University, Princeton, NJ, USA.
Nat Cancer
November 2024
Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Am J Lifestyle Med
December 2023
Department of Orthopaedic Surgery, Division of Physical Medicine and Rehabilitation, Washington University in St. Louis School of Medicine, St. Louis, MO, USA (ALC, MED, AM, CGL, DEF, KHB, DMH).
Background: Therapeutic lifestyle change can be challenging, and not every attempt is successful.
Purpose: To identify predictors of making progress toward lifestyle change among patients who participate in a lifestyle medicine program.
Methods: This was a single-center, retrospective cohort study of 205 adults who enrolled in a goal-directed, individualized, interprofessional lifestyle medicine program.
Ann Surg Oncol
January 2025
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Cancer Prev Res (Phila)
January 2025
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Mammographic density is a strong risk factor for breast cancer and is reported clinically as part of Breast Imaging Reporting and Data System (BI-RADS) results issued by radiologists. Automated assessment of density is needed that can be used for both full-field digital mammography (FFDM) and digital breast tomosynthesis (DBT) as both types of exams are acquired in standard clinical practice. We trained a deep learning model to automate the estimation of BI-RADS density from a prospective Washington University clinic-based cohort of 9,714 women, entering into the cohort in 2013 with follow-up through October 31, 2020.
View Article and Find Full Text PDFSci Adv
October 2024
Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO, USA.
An important subset of meningiomas behaves aggressively and is characterized by multiple recurrences. We identify clinical, genetic, and epigenetic predictors of multiply recurrent meningiomas (MRMs) and evaluate the evolution of these meningiomas in patient-matched samples. On multivariable binomial logistic regression, MRMs were significantly associated with male sex ( = 0.
View Article and Find Full Text PDFSci Transl Med
October 2024
Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy that is often resistant to therapy. An immune suppressive tumor microenvironment (TME) and oncogenic mutations in have both been implicated as drivers of resistance to therapy. Mitogen-activated protein kinase (MAPK) inhibition has not yet shown clinical efficacy, likely because of rapid acquisition of tumor-intrinsic resistance.
View Article and Find Full Text PDFBlood Cancer J
October 2024
Divsion of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( > 20%) as well as increased numbers of large B cells (LC). However, there are limited data available demonstrating the prognostic significance of these variables in patients with MZL. In this multi-institutional retrospective cohort study of patients with MZL treated at 10 centers, we evaluated the association between the presence of Ki-67 expression and increased LCs on survival and risk of histologic transformation (HT).
View Article and Find Full Text PDFMol Cancer Res
January 2025
Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina.
Prostate cancer is a heterogeneous disease with a spectrum of pathology and outcomes ranging from indolent to lethal. Although there have been recent advancements in prognostic tissue biomarkers, limitations still exist. We leveraged matrix-assisted laser desorption/ionization imaging of formalin-fixed, paraffin embedded prostate cancer specimens to determine if N-linked glycans expressed in the extracellular matrix of lethal neuroendocrine prostate cancer were also expressed in conventional prostate adenocarcinomas that were associated with poor outcomes.
View Article and Find Full Text PDFbioRxiv
October 2024
Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.
Arthritogenic alphaviruses cause disease characterized by fever, rash, and incapacitating joint pain. Alphavirus infection stimulates robust inflammatory responses in infected hosts, leading to the upregulation of several cytokines, including granulocyte colony-stimulating factor (G-CSF). G-CSF is secreted by endothelial cells, fibroblasts, macrophages, and monocytes and binds to colony stimulating factor 3 receptor (CSF3R, also known as G-CSFR) on the surface of myeloid cells.
View Article and Find Full Text PDFbioRxiv
October 2024
Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA.
Obesity induces diverse changes in host immunity, resulting in worse disease outcomes following infection with various pathogens, including arthritogenic alphaviruses. However, the impact of obesity on the functional landscape of immune cells during arthritogenic alphavirus infection remains unexplored. Here, we used single-cell RNA sequencing (scRNA-seq) to dissect the blood and tissue immune responses to Mayaro virus (MAYV) infection in lean and obese mice.
View Article and Find Full Text PDFJ Natl Compr Canc Netw
October 2024
National Comprehensive Cancer Network.
N Engl J Med
October 2024
From City of Hope Comprehensive Cancer Center, Duarte (A.F.H., M.G.M., J.Y.S.), University of California Davis Comprehensive Cancer Center, Sacramento (J.M.T.), and Children's Hospital Los Angeles, Los Angeles (C.F., A.D., A.K.) - all in California; SWOG Statistics and Data Management Center, Fred Hutchinson Cancer Center, (M.L., H.L.) and Seattle Children's Hospital (A.L.) - both in Seattle; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta (S.M.C.), and Winship Cancer Institute and Emory University Hospital (K.A.B.), Atlanta; Weill Cornell Medicine (S.C.R., J.P.L.), Memorial Sloan Kettering Cancer Center (P.T.), and New York University Langone (L.K.S.), New York, Wilmot Cancer Institute, University of Rochester, Rochester (C.C., L.S.C., J.W.F.), and Roswell Park Comprehensive Cancer Center, University at Buffalo, Buffalo (K.M.K.) - all in New York; Rutgers Cancer Institute of New Jersey, New Brunswick (A.M.E.); McGill University Health Centre, Montreal (K.D.), and SickKids Hospital (Angela Punnett) and Princess Margaret Cancer Centre (D.H., Anca Prica, M.C.), Toronto - all in Canada; Reid R. Sacco AYA Cancer Program, Tufts Medical Center (S.K.P.), and Dana-Farber Cancer Institute (M.A.S.) - both in Boston; M.D. Anderson Cancer Center, Houston (S.A.), and University of Texas Health Science Center at San Antonio, San Antonio (S.K.) - both in Texas; Siteman Cancer Center, Washington University, St. Louis (N.L.B., B.K.); Medical University of South Carolina, Charleston (B.T.H.), and Prisma Health Cancer Institute - Eastside, Greenville (S.C.) - both in South Carolina; Carolinas Medical Center, Levine Cancer Institute, Charlotte, NC (R.J.); Moffitt Cancer Center, Tampa (H.S.), and Sylvester Comprehensive Cancer Center, University of Miami, Miami (C.M.) - both in Florida; Huntsman Cancer Institute, University of Utah, Salt Lake City (B.H.); University of Alabama at Birmingham, Birmingham (G.G.); Illinois CancerCare, Peoria (P.K.), and University of Chicago, Chicago (S.M.S.); Cancer and Hematology Centers of Western Michigan, Grand Rapids (B.B.), and University of Michigan, Ann Arbor (A.M.P.); the Department of Hematology and Oncology, Geisinger Community Medical Center, Scranton, PA (N.S.); Fairview Ridges Hospital, Minnesota Oncology, Burnsville (A.S.); SWOG Cancer Research Network, Teaneck, NJ (H.D.); and the National Cancer Institute, Cancer Therapy Evaluation Program, Bethesda, MD (R.F.L.).
Clin Nucl Med
January 2025
From the Mallinckrodt Institute of Radiology and Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
68 Ga-DOTATATE PET/CT targeting somatostatin receptors is commonly utilized in the imaging of neuroendocrine tumors. However, other malignancies such as lymphomas (both Hodgkin and non-Hodgkin) also have expression of somatostatin receptors, albeit to a lesser degree compared with the neuroendocrine tumors, and thus can be positive on a 68 Ga-DOTATATE PET/CT. We describe an atypical presentation of an aggressive large B-cell lymphoma mimicking a metastatic neuroendocrine tumor at initial presentation with high somatostatin receptor expression demonstrated on the 68 Ga-DOTATATE PET/CT and a rapidly progressing course on the subsequent 18 F-FDG PET/CT.
View Article and Find Full Text PDFSci Rep
October 2024
Department of Medicine, Division of Molecular Oncology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8069, St. Louis, MO, 63110, USA.